Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years

被引:86
|
作者
Zivadinov, R. [1 ,2 ]
Bergsland, N. [1 ]
Dolezal, O. [3 ,4 ]
Hussein, S. [1 ]
Seidl, Z. [5 ]
Dwyer, M. G. [1 ]
Vaneckova, M. [5 ]
Krasensky, J. [5 ]
Potts, J. A. [7 ]
Kalincik, T. [3 ,4 ,6 ]
Havrdova, E. [3 ,4 ]
Horakova, D. [3 ,4 ]
机构
[1] SUNY Buffalo, Buffalo Neuroimaging Anal Ctr, Buffalo, NY 14203 USA
[2] SUNY Buffalo, Jacobs Neurol Inst, Buffalo, NY 14203 USA
[3] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic
[4] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Dept Radiol, Prague, Czech Republic
[6] Univ Melbourne, Dept Med, Melbourne Brain Ctr, Melbourne, Vic 3010, Australia
[7] Biogen Idec Inc, Weston, MA USA
关键词
GRAY-MATTER ATROPHY; CLINICALLY ISOLATED SYNDROMES; VOXEL-BASED ANALYSIS; MULTIPLE-SCLEROSIS; BRAIN ATROPHY; GREY-MATTER; INTERFERON BETA-1A; MODERN VIEWS; FOLLOW-UP; IMAGES;
D O I
10.3174/ajnr.A3503
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: Pathologic changes in GM have an important role in MS. We investigated the association between SDGM and cortical volume changes and disability progression in early RRMS. MATERIALS AND METHODS: One hundred eighty patients with RRMS had clinical assessment during 5 years and were divided into those with or without SDP at 5 years by the usual definition in treatment trials. The number of available MR imaging scans at various time points was the following: at baseline, 178; and at 6 months, 172; at 12 months, 175; at 24 months, 155; at 36 months, 160; at 48 months, 158; and at 60 months, 162, respectively. Longitudinal changes in cortical, GM, and WM volume were calculated by using the direct method. RESULTS: At 5 years, 90 patients with RRMS experienced SDP and 90 had stable disease. At baseline, patients with SDP had longer disease duration, greater T2-lesion volume, and smaller whole-brain, WM, cortical, and SDGM volume (P < .01). At 5 years, patients with SDP had significantly greater percentage decreases from baseline compared with those without SDP in the volume of the whole brain (P < .0001), cortex (P = .001), GM (P = .003), and thalamus (P = .01). In patients who developed SDP at 5 years and those who did not, mixed-effect models, adjusted for age, disease duration, and change of the treatment status, showed significant interactions between SDP status at 5 years and changes with time in whole-brain, cortical, lateral ventricle (all P < .001), thalamus (P = .006), and total SDGM (P = .0095) volume. CONCLUSIONS: SDP is associated with progression of cortical, central, and thalamic atrophy in early RRMS during 5 years.
引用
收藏
页码:1931 / 1939
页数:9
相关论文
共 50 条
  • [21] Correlation between functional MRI techniques and early disability in ambulatory patients with relapsing-remitting MS
    Mohamed, Al-Amir Bassiouny
    Algahalan, Hesham Abdelghani
    Thabit, Mohamed N.
    EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2022, 58 (01):
  • [22] Predicting the course of relapsing-remitting MS using longitudinal disability curves
    Anat Achiron
    Journal of Neurology, 2004, 251 : v65 - v68
  • [23] The transition from relapsing-remitting MS to irreversible disability: clinical evaluation
    Trojano, M
    Paolicelli, D
    Bellacosa, A
    Cataldo, S
    NEUROLOGICAL SCIENCES, 2003, 24 (Suppl 5) : S268 - S270
  • [24] Multimodal evoked potentials measure and predict disability progression in early relapsing-remitting multiple sclerosis
    Jung, P.
    Beyerle, A.
    Ziemann, U.
    MULTIPLE SCLEROSIS, 2008, 14 (04): : 553 - 556
  • [25] The transition from relapsing-remitting MS to irreversible disability: clinical evaluation
    M. Trojano
    D. Paolicelli
    A. Bellacosa
    S. Cataldo
    Neurological Sciences, 2003, 24 : s268 - s270
  • [26] Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
    Giovannoni, Gavin
    Cohen, Jeffrey A.
    Coles, Alasdair J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Margolin, David H.
    Lake, Stephen L.
    Kaup, Susan M.
    Panzara, Michael A.
    Compston, D. Alastair S.
    NEUROLOGY, 2016, 87 (19) : 1985 - 1992
  • [27] Predicting the course of relapsing-remitting MS using longitudinal disability curves
    Achiron, A
    JOURNAL OF NEUROLOGY, 2004, 251 (Suppl 5) : 65 - 68
  • [28] Cognitive decline predicts disability progression in relapsing-remitting multiple sclerosis
    Vermersch, Patrick
    Leuse, Delphine
    Cabaret, Maryline
    Outteryck, Olivier
    de Seze, Jerome
    Dujardin, Kathy
    Zephir, Helene
    MULTIPLE SCLEROSIS, 2008, 14 : S266 - S266
  • [29] Interferon-beta and disability progression in relapsing-remitting multiple sclerosis
    Drulovic, Jelena
    Kostic, Jelena
    Mesaros, Sarlota
    Basuroski, Irena Dujmovic
    Stojsavljevic, Nebojsa
    Kisic-Tepavcevic, Darija
    Pekmezovic, Tatjana
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 : S65 - S69
  • [30] Benign multiple sclerosis and relapsing-remitting MS differ in cortical pathology
    Calabrese, M.
    Bernardi, V.
    Atzori, M.
    Rinaldi, L.
    Barachino, L.
    Morra, A.
    Grossi, P.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2006, 12 : S172 - S172